PDCD1 and head and neck squamous cell carcinoma: Programmed cell death 1 (PD-1) inhibitors nivolumab and pembrolizumab have been approved for the treatment of recurrent/metastatic HNSCC, with a prolonged OS compared with chemotherapy16–18.